Omar Jawdat, MD
Neurology · Kansas City, KSNPI 1992941181
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $250 of the $279 with a category attached, or 89.8%. Hospira, Inc. accounts for 73.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $111 and has fallen 81.7% since, to $20 in 2025. That places this record below the midpoint for neurology clinicians in KS, where the typical reported total is $830.
Across 17 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hospira, Inc.$206
- Tanabe Pharma America, Inc.$28
- Argenx US, Inc.$18
- EDW Pharma, Inc.$15
- Shire North American Group Inc$12
Across 43 payments — averaging $2580.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$44K
- Biohaven Pharmaceutical Holding Company Ltd.$24K
- AstraZeneca$21K
- UCB SA$18K
- Mallinckrodt Enterprises LLC$4K
What the payments were for
- Food & beverage$25090%
- Education$2810%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hospira, Inc. | 13 | $206 |
| Tanabe Pharma America, Inc. | 1 | $28 |
| Argenx US, Inc. | 1 | $18 |
| EDW Pharma, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$279 in reported general payments places this provider in the 35th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 78 | $1,128,675 |
| SolirisEculizumab | 13 | $678,392 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 43 | $462,104 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 36 | $243,119 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $131,227 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $53,242 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $49,525 |
| TeglutikRiluzole | 12 | $45,773 |
| Riluzole | 89 | $25,745 |
| Pyridostigmine Bromide | 95 | $11,802 |
| Mycophenolate Mofetil | 46 | $3,629 |
| Pregabalin | 63 | $3,563 |
| Azathioprine | 47 | $3,007 |
| Gabapentin | 62 | $2,395 |
| Ranolazine ErRanolazine | 18 | $1,860 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Jeffrey BurnsKansas City$115K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.